Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
NCT ID: NCT04247906
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MAP to Provide Access to Eltrombopag, for Treatment of Patients With Medically Significant Thrombocytopenia
NCT04837703
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
NCT01484314
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
NCT01623167
Avatrombopag to Promote Platelet Engraftment After Allo-HSCT
NCT05143892
Eltrombopag for Post Transplant Thrombocytopenia
NCT01000051
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Narsoplimab
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient must be capable of understanding an informed consent form (ICF) or the parent or legal guardian of the patient is able to understand and sign a written ICF prior to the initiation of any treatment procedures.
* Patient must have HSCT- TMA defined as having thrombocytopenia and evidence of microangiopathic hemolytic anemia.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Impatients N.V. trading as myTomorrows
INDUSTRY
Omeros Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
721-TMA-EA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.